SHAREHOLDER ALERT: WeissLaw LLP Reminds DSPG, ADTN, TRIL, and STMP Shareholders About Its Ongoing Investigations

-

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16 th Floor
New York , NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

DSP Group, Inc. (NASDAQ: DSPG)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of DSP Group, Inc. (NASDAQ: DSPG ) in connection with the proposed acquisition of the company by Synaptics Incorporated. Under the terms of the merger agreement, the company's shareholders will receive $22.00 per share in cash for each share of DSPG common stock that they hold. If you own DSPG shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/dspg

ADTRAN, Inc. (NASDAQ: ADTN)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ADTRAN, Inc. (NASDAQ: ADTN) in connection with the proposed stock-for-stock merger of the company with ADVA ("ADVA"). ADTN and ADVA will combine under a new holding company, which will be renamed ADTRAN Holdings, Inc. following the closing. Under the terms of the merger agreement, each ADVA share will be exchanged for 0.8244 shares of the new holding company. ADTN shares will be exchanged for shares in the new holding company on a one-for-one basis. At the closing, ADTN shareholders will own approximately 54% of the equity of the combined company and ADVA shareholders will own approximately 46%. If you own ATDN shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/adtn

Trillium Therapeutics Inc. (NASDAQ: TRIL)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Trillium Therapeutics Inc. (NASDAQ: TRIL) in connection with the proposed acquisition of the company by Pfizer Inc. Under the terms of the merger agreement, the company's shareholders will receive $18.50 per share in cash for each share of TRIL common stock that they hold. If you own TRIL shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/tril

Stamps.com Inc. (NASDAQ: STMP)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Stamps.com Inc. (NASDAQ: STMP) in connection with the proposed acquisition of the company by Thoma Bravo , L.P. Under the terms of the merger agreement, the company's shareholders will receive $330.00 per share in cash for each share of STMP common stock that they hold. If you own STMP shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/stmp

View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-dspg-adtn-tril-and-stmp-shareholders-about-its-ongoing-investigations-301376723.html

SOURCE WeissLaw LLP

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
  BPH Global Ltd

120-Day Business Development Plan

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company’s CEO Matthew Leonard and CFO Chow Yee Koh are currently travelling in Malaysia and China for a series of meetings over a 2–3- week period commencing last week. The CEO and CFO will be joined by China-based Company Director Michael Huang for strategic meetings in Malaysia and China.

Keep reading...Show less
  BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

Keep reading...Show less
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
double helix molecule with word "etf"

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of March 8, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.

Keep reading...Show less

Latest Press Releases

Related News

×